Alzheimer's disease (AD) is a growing health crisis - nearly 7 million Americans (³65 years) are currently affected with estimated care costs of $360 billion and the numbers affected and costs are projected to grow alarmingly as the population ages. AD is increasingly recognized as a chronic neuroinflammatory disease. MindImmune's MITI-101 is a novel therapeutic that blocks the recruitment of CD11c+ immune cells into brain that cause this chronic neuroinflammation. By breaking the neuroinflammatory cycle,MITI-101 will improve symptoms and slow progression of dementia when most practically needed, at the time of AD diagnosis.